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Abstract
Background: Betaine insufficiency is associated with unfavourable vascular risk profiles in metabolic syndrome patients. We
investigated associations between betaine insufficiency and secondary events in acute coronary syndrome patients.
Methods: Plasma (531) and urine (415) samples were collected four months after discharge following an acute coronary
event. Death (34), secondary acute myocardial infarction (MI) (70) and hospital admission for heart failure (45) events were
recorded over a median follow-up of 832 days.
Principal Findings: The highest and lowest quintiles of urinary betaine excretion associated with risk of heart failure
(p=0.0046, p=0.013 compared with middle 60%) but not with subsequent acute MI. The lowest quintile of plasma betaine
was associated with subsequent acute MI (p=0.014), and the top quintile plasma betaine with heart failure (p=0.043),
especially in patients with diabetes (p,0.001). Top quintile plasma concentrations of dimethylglycine (betaine metabolite)
and top quintile plasma homocysteine both associated with all three outcomes, acute MI (p=0.004, ,0.001), heart failure
(p=0.027, p,0.001) and survival (p,0.001, p,0.001). High homocysteine was associated with high or low betaine excretion
in .60% of these subjects (p=0.017). Median NT-proBNP concentrations were lowest in the middle quintile of plasma
betaine concentration (p=0.002).
Conclusions: Betaine insufficiency indicates increased risk of secondary heart failure and acute MI. Its association with
elevated homocysteine may partly explain the disappointing results of folate supplementation. In some patients, especially
with diabetes, elevated plasma betaine also indicates increased risk.
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Introduction
Betaine (N,N,N-trimethylglycine) is an essential osmolyte and
methyl group donor [1–4] that also affects lipid partitioning [5]. Its
metabolism (Figure 1) links several metabolites that play an
important role in the health of humans and other mammals,
including choline (an important source of betaine), and homocys-
teine and methionine which are involved in its catabolism. Cross-
sectional data [6–8] hint that betaine insufficiency may be
associated with vascular disease, especially in subjects with the
metabolic syndrome [3], but the evidence is circumstantial. Low
plasma betaine is common in subjects with an unfavourable
vascular risk profile [7,8], but plasma betaine is only modestly
correlated with tissue betaine [9]; because of its role as an
osmolyte, betaine concentrations are much higher in most tissues
than in blood [9]. Normally minimal amounts are lost in the urine,
even after a substantial betaine load [10–11], showing that the
normal pathway for elimination is by catabolism. The strong
homeostatic control of plasma and urine betaine [12–14] is only
minimally affected by osmotic changes, despite large changes in
tissue betaine concentrations, and there is no correlation between
plasma betaine concentrations and urinary betaine excretions.
Thus while low plasma betaine could be associated with a tissue
betaine insufficiency, the plasma concentration is a limited marker.
An insufficiency could be the result of excessive loss or defective
metabolism of choline to betaine [3], and these could be
exacerbated by poor dietary choices. However, other cross-
sectional evidence has also associated elevated plasma betaine
with vascular disease [15]. This presumably reflects a different
pathology; the plasma betaine concentrations in this study were
still well below tissue concentrations and the elevations could
reflect (for example) defective retention of intracellular betaine in
some tissues.
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load test may be a test of betaine sufficiency [3,16] but it is not
practicable to screen seriously ill subjects with this test. Neverthe-
less, some biochemical markers may indicate at least some cases of
betaine insufficiency. Unusually low plasma betaine is one.
Another is a high urinary betaine loss, which could be expected
to cause a deficiency; patients with diabetes or renal failure often
have either abnormally high or abnormally low betaine excretion
[3,13]. Subjects with a severe betaine insufficiency for some other
reason could also be expected to have unusually low betaine
excretion. Raised plasma dimethylglycine [3] indicates an
increased catabolism of betaine (a response to homocysteine
accumulation), and a reduced supply of betaine is an important
cause of elevated fasting plasma homocysteine [2,3]. If homocys-
teine is elevated in response to a betaine insufficiency, it will not be
corrected by B-vitamin supplementation. This could help to
explain why this treatment does not lead to the expected reduction
in vascular events [17–19]; possibly the elevated homocysteine is a
marker of betaine insufficiency in a subset of the study populations,
rather than causal.
The aim of the present study was to prospectively relate
potential markers of betaine insufficiency to acute MI and heart
failure, in a high-risk population with established vascular disease.
This population would therefore be expected to be enriched with
subjects with an abnormal betaine status at baseline.
Methods
Ethics
Study protocols were approved by the Canterbury Ethics
Committee. All subjects gave written informed consent. The
investigation conforms to the principles outlined in the Declaration
of Helsinki and Title 45, US Code of Federal Regulations, Part 46
and with published accepted principles [20].
Subjects
Subjects in the present betaine sub-study were part of an Acute
Coronary Syndrome (ACS) cohort recruited by the Christchurch
Cardioendocrine Group, Christchurch Hospital [21]. Eligible
subjects were recruited following hospitalization for ACS defined
by a history of ischemic chest pain plus one or more of the
following: ECG changes (ST segment depression or elevation of at
least 0.5 mm, T-wave inversion of at least 3 mm in at least 3 leads,
or left bundle branch block), elevated levels of cardiac markers, a
history of coronary disease, or age of at least 65 years in patients
with diabetes or vascular disease. These are identical to the criteria
used in the OPUS-TIMI 16 trial and by De Lemos et al. [22].
Exclusion criteria included severe co-morbidity limiting life
expectancy to less than 3 years and inability to provide written
informed consent. For the betaine sub-study fasting plasma
samples were collected on 531 subjects, and matching urine
samples on 415 of these, at the four-month post-discharge follow-
up outpatient clinic visit (Table 1). The patients were expected to
have stabilized by this visit.
Follow up
In the present sub-study, subjects were followed for a median of
832 days (IQ range 621–991 days) from enrolment. Clinical events
were determined from recruitment questionnaires, planned follow-
up clinic visits for all patients, patient notes, and the New Zealand
Health Information Service and hospital Patient Management
System databases. Clinical endpoints included all-cause mortality,
hospitalization for acute decompensated heart failure [23] and
hospitalization for acute MI [24]. Diagnoses at hospitalisation
were defined using the International Statistical Classification of
Diseases and Health Related Health Problems 10th Revision
(ICD-10).
Laboratory methods
Betaine and N,N-dimethylglycine were measured in plasma and
urine by HPLC after separation of their 2-naphthacyl derivatives
on Merck Aluspher alumina columns [25,26]. Comparative data
on normal subjects has been reviewed elsewhere [3]. Plasma N-
terminal pro-brain natriuretic peptide (NT-proBNP) was estimated
as previously described [27]. Plasma homocysteine was measured
by fluorescence polarization on an Abbott IMX Analyzer (Abbott
Laboratories USA). Other biochemical measures in plasma and
urine were carried out using an Abbott ARCHITECT ci8200
Analyzer (Abbott Laboratories) by standard kit procedures in an
International Accreditation New Zealand accredited laboratory.
Excretions were expressed as mmoles betaine or N,N-dimethyl-
glycine per mole creatinine, which has been shown to be a robust
measure [14].
Figure 1. Betaine metabolism. Metabolic pathways involving betaine. BHMT: betaine homocysteine methyltransferase, a zinc metalloenzyme
abundant in human liver and kidney tissues. SAM: S-adenosylmethionine, ubiquitous methyl-group donor in human metabolism.
doi:10.1371/journal.pone.0037883.g001
Betaine and Events
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37883Statistical analyses
Statistical analyses were carried out using SigmaPlot for
Windows version 11.2 (Systat Software Inc). Significance was
taken as p,0.05. Urine betaine excretion may be either
abnormally high or low in disease [13], and therefore we divided
data for all variables into quintiles (for both urine and plasma) and
compared time to event in each of the top and bottom quintiles
with the central 60% of the sample population. When significant
effects were identified from these comparisons these were further
explored by comparisons among all 5 quintiles. Kaplan-Meier
cumulative plots, with death (all-cause), secondary acute MI or
hospital admission for heart failure as end-points, were used to
illustrate comparisons between quintile groups. Statistical signif-
icance was determined using log-rank comparisons. Plasma
betaine and N,N-dimethylglycine concentrations were adjusted
for gender (the mean male betaine concentration was 20.5%
higher than the female mean; dimethylglycine was 11.7% higher
in males).
The primary urine results are reported on a population
excluding subjects taking fibrates (n=390) because fibrates cause
large increases in betaine excretion [28].
Multiple linear regression was used to determine whether
plasma betaine, homocysteine or urine betaine excretion were
independently associated with an established marker of cardiac
injury, plasma NT-proBNP concentration. NT-proBNP and
plasma homocysteine levels were log transformed prior to analyses.
Cox proportional hazards model regression was used to determine
the independence of prognostic markers along with baseline left
ventricular ejection fraction, age and gender. Because of evidence
that both high and low results were associated with increased
events, high (top quintile) and low (bottom quintile) were
compared with the middle 60% as categorical variables.
Table 1. Study population.
Females Males
Number 148 383
Median age (total range)** 73 (51–91) 67 (55–93)
Follow-up time/time to death (median, IQ range) days 878 (657–1005) 825 (600–988)
With diabetes
{, n(%) 28 (19%) 65 (17%)
Previous MI, n(%) 37 (25%) 133 (35%)
Secondary acute MI, n(%) 16 (11%) 54 (14%)
Heart failure, n(%) 13 (9%) 32 (8%)
Deaths (all-cause), n(%) 7 (5%) 27 (7%)
Left ventricular ejection fraction (median, IQ range) %*** 63 (55–68) 58 (50.5–63)
Waist (median, IQ range) cm*** 89 (80–97) 97 (90–103)
BMI (median, IQ range) kg/m
2 27.0 (22.7–31.6) 26.5 (24.5–29.4)
Biochemical and hematological parameters:
Hemoglobin (median, IQ range) g/L*** 132.5 (122–140) 143.5 (136–152)
Plasma creatinine (median, IQ range) mmol/L*** 80 (70–95) 100 (90–112)
Plasma urea (median, IQ range) mmol/L* 6.1 (4.9–7.8) 6.6 (5.5–8.5)
Plasma homocysteine (median, IQ range) mmol/L 12.5 (10.2–15.6) 12.6 (10.6–16.3)
Plasma NT-proBNP (median, IQ range) pmol/L 87.0 (45.9–178) 79.9 (34.7–168)
Plasma betaine (median, IQ range) mmol/L*** 38.9 (30.8–46.0) 44.5 (35.0–57.5)
Plasma DMG (median, IQ range) mmol/L* 3.4 (2.2–4.8) 3.8 (2.7–5.2)
Urine betaine/creatinine (median, IQ range) mmol/mole cr 8.2 (4.4–17.7) 9.2 (5.9–17.6)
Urine DMG/creatinine (median, IQ range) mmol/mole cr 2.4 (1.4–4.3) 2.9 (1.5–5.9)
Smoking:
Current smokers, n(%) 12 (8%) 20 (5%)
Past smokers, n(%)*** 65 (44%) 241 (63%)
Never smoked, n(%)*** 71 (48%) 123 (32%)
Medications:
Taking ACE inhibitors, n(%) 76 (51%) 212 (55%)
Taking b-blocker drugs, n(%) 123 (83%) 328 (86%)
Taking statins, n(%)* 118 (80%) 336 (88%)
Taking aspirin, n(%) 138 (93%) 354 (92%)
Taking Clopidogrel, n(%)* 47 (32%) 156 (41%)
cr: creatinine. DMG: N,N-dimethylglycine. IQ: interquartile. NT-proBNP: N-terminal peptide of B-type natriuretic peptide. Significance of gender differences:
*p,0.05;
**p,0.01;
***p,0.001.
{Three patients (2 female, 1 male) with Type 1 diabetes, remainder all Type 2.
doi:10.1371/journal.pone.0037883.t001
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Study population
The study population (Table 1) was predominantly (72%)
male. The standard prescribed medications for coronary patients
were present in most cases.
Association with events
Plasma and urine betaine and betaine metabolites were
significantly related to time to event (Table 2). Both high and
low urinary excretions of betaine were significantly associated with
admission for heart failure. The results remained significant when
subjects treated with fibrates were included. Low plasma betaine
concentrations were associated with acute MIs while high plasma
betaine concentrations were associated with admission for heart
failure. High plasma concentrations of N,N-dimethylglycine and
homocysteine were significantly associated with all events, but we
did not demonstrate any associations for low levels of either.
Details in quintiles of plasma betaine and homocysteine
concentrations
The prognostic significance of plasma betaine and homocyste-
ine was further examined by comparing outcome in all quintiles of
each (Figure 2). For all events, the best outcome was for subjects
in the second highest quintile of plasma betaine (plasma betaine
concentrations 50–60 mmol/L for males, 41–50 mmol/L for
females). Compared with this quintile, subjects in both the top
quintile, p=0.015, of plasma betaine and (especially) the bottom
quintile (,34 mmol/L males, ,28 mmol/L females), p=0.002,
had an increased risk of secondary acute MI. Only the top quintile
showed a significantly increased risk of admission with heart
failure (p=0.019). Early events tended to be associated with the
top quintile of plasma betaine concentrations (Figure 2 A&B).
Only subjects with homocysteine concentrations in the top
quintile (.17 mmol/L) of this population had significantly poorer
outcomes (Figure 2 C&D). Even subjects in the second top
homocysteine quintile (13–17 mmol/L), normally regarded as
having elevated homocysteine, were not at significantly greater
risk. In fact, the increased risk was mainly associated with the top
10% (plasma homocysteine .20.5 mmol/L).
Diabetes frequently alters betaine excretion. In the subjects
without diabetes (not taking fibrates, n=325), only high urinary
betaine excretion was confirmed as a risk factor for heart failure
(p=0.010). The number of subjects with diabetes (n=64) was too
small for conclusive results, but the trend (p=0.19) was for low,
Table 2. Predictors of events.
Outcome; mean survival, days (p – value)
Predictor Death AMI HF
Plasma betaine middle quintiles 1390 1332 1373
Plasma betaine high (.60.6 mmol/L) 1434 (0.7) 1294 (0.18) 1321 (0.043)
Plasma betaine low (,33.8 mmol/L) 1354 (0.6) 1198 (0.014) 1336 (0.5)
Plasma DMG middle quintiles 1441 1252 1379
Plasma DMG high (.5.8 mmol/L) 1270 (,0.001) 1155 (0.004) 1245 (0.027)
Plasma DMG low (,2.5 mmol/L) 1340 (0.3) +0.4 (0.5) 1377 (0.12)
Urine betaine excr. middle quintiles 1406 1349 1444
Urine betaine excr. high (.19.5) 1390 (0.5) 1283 (0.6) 1276 (0.005)
Urine betaine excr. low (,4.6) 1425 (0.055) 1301 (0.9) 1291 (0.013)
Plasma homocysteine middle quintiles 1441 1380 1434
Plasma homocysteine high (.17.0 mmol/L) 1215 (,0.001) 930 (,0.001) 987 (,0.001)
Plasma homocysteine low (,10.0 mmol/L) 1459 (0.13) 1390 (0.6) 1459 (0.092)
Comparisons of the middle three quintiles with the top quintile (‘‘high’’) and lowest quintile (‘‘low’’) for possible predictors of events. Mean survival times to events
given in days, with p values (in brackets) for the difference in risk compared with the middle 60% of the population. Significant (p,0.05) statistics are in bold. DMG: N,N-
dimethylglycine. AMI: acute MI. HF: hospital admission for heart failure. Betaine excretions expressed as mmol betaine/mole creatinine. Plasma betaine and DMG
concentrations are gender corrected; male values cited (female values 17% lower for betaine, 10% lower for DMG).
doi:10.1371/journal.pone.0037883.t002
Figure 2. Outcomes in quintiles. Kaplan-Meier curves for time to
first secondary event after samples taken: A & B: quintiles of gender-
adjusted plasma betaine concentrations, A without acute MI, B without
admission to hospital for heart failure; C & D: quintiles of plasma
homocysteine concentrations, C without acute MI, D without admission
to hospital for heart failure. Significance based on log-rank statistic for
paired comparisons.
doi:10.1371/journal.pone.0037883.g002
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outcomes (admissions for heart failure). There were clearer
differences between the groups in the relationship between plasma
betaine and MI (Figure 3 A&C): in subjects without diabetes
(n=410), patients with low plasma betaine were more likely to
have an event (p=0.007) whereas in the patients with diabetes
those with elevated plasma betaine had a significantly greater risk
(p=0.017). However, given the small sample size, the risk
associated with low plasma betaine may be similar in this group
(p=0.102) to that in the patients without diabetes. In the subjects
with diabetes, plasma betaine was a significant predictor for
admission for heart failure (Figure 3 B&D), with the top quintile
having a higher risk than the second-top quintile (p,0.001). Again,
given the small numbers, it is possible that heart failure may also
be associated with low plasma betaine (for the difference between
the second top and bottom quintiles p=0.060).
The plasma betaine quintiles defined groups with similar
concentrations of plasma creatinine and plasma urea, and age
(Table 3). The quintiles differ in median BMI and non-HDL
cholesterol, consistent with previous reports [7,8] that elevations in
these are associated with low plasma betaine. Plasma NT-proBNP
was also different between the quintiles of plasma betaine, with the
lowest concentrations in the middle quintile (Table 3).
NT-proBNP, betaine and homocysteine
The trend for NT-proBNP to be elevated either when plasma
betaine is low or is elevated (Table 3) was confirmed (p,0.001) by
further dividing the population into deciles of plasma betaine
concentration. There was a clear minimum median NT-proBNP
in the middle deciles, with both the lowest and top deciles of
plasma betaine having higher median NT-proBNP (Figure 4).
In a multiple regression model that included age and the
presence of renal disease as factors, the log of plasma homocys-
teine concentration (p,0.001) and plasma betaine concentration
(p=0.007) were significantly associated with the log of the NT-
proBNP concentration. Both factors were positive predictors, and
independent (variance inflation factors ,1.5), with overall
r
2=0.50. Age was also an independent significant predictor
(p,0.001) but the presence of renal disease was not significant.
Homocysteine and betaine excretion
Subjects with elevated plasma homocysteine tended to have
either high or low betaine excretions, irrespective of whether
subjects treated with fibrates were included. Patients with either
high (top quintile) or low (bottom quintile) betaine excretion were
Figure 3. Effect of diabetes. Kaplan-Meier curves for time to first
secondary events after samples taken: A & B subjects without diabetes,
A time without acute MI, B time without admission to hospital with
heart failure; C & D subjects with diabetes, C time without acute MI, D
time without admission to hospital with heart failure. Quintiles (based
on whole population) of gender-adjusted plasma betaine concentra-
tions. Significance based on log-rank statistic for paired comparisons.
doi:10.1371/journal.pone.0037883.g003
Table 3. Differences between plasma betaine quintiles.
p Q1 Q2 Q3 Q4 Q5
Pl betaine (mmol/L) .. 28.9 37.6 45.3 54.2 70.0
Age (years) 0.46 66 68 68 68 70
BMI 0.002 28.0 27.2 26.4 26.5 25.3
Left ventricular ejection fraction 0.14 60 58 60 60 57
Pl creatinine (mmol/L) 0.31 99 90 100 92 90
Pl urea (mmol/L) 0.28 6.5 5.9 6.5 6.7 6.5
Pl homocysteine (mmol/L) 0.12 13.5 12.3 12.6 12.5 12.3
Pl Non-HDL cholesterol
(mmol/L)
,0.0013.38 2.98 3.22 2.97 2.64
Pl NT-proBNP (pmol/L) 0.002 71 46 45 71 101
With diabetes (%) 0.18 15 24 18 17 11
Median data in subsets of study population based on quintiles of gender-
adjusted plasma (pl) betaine concentrations from Q1 (lowest quintile) to Q5
(highest quintile), with significance (p) for difference between quintiles (Kruskal-
Wallis one way analysis of variance on ranks). Significant (p,0.05) differences
between quintiles marked in bold. ‘‘With diabetes’’ row shows percentage of
subjects in each plasma betaine quintile who had diabetes.
doi:10.1371/journal.pone.0037883.t003
Figure 4. NT-proBNP and plasma betaine. Median NT-proBNP
concentrations of deciles of gender-corrected plasma betaine concen-
trations; trend (quadratic regression) and 95% confidence intervals
shown (p,0.001).
doi:10.1371/journal.pone.0037883.g004
Betaine and Events
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37883considered to have ‘‘unusual betaine excretion’’. In subjects not
taking fibrates, 64% of the high homocysteine (.20 mmol/L)
subjects had an unusual betaine excretion compared with 39% in
the subjects with plasma homocysteine ,20 mmol/L (p=0.017). If
subjects taking fibrates were included in the comparison the same
pattern was found (p=0.005).
Baseline left ventricular ejection fraction, plasma and
urine betaine and age.
Cox proportional hazards regression models with age and
baseline left ventricular ejection fraction as continuous variables,
and gender and betaine groups (Table 2) as categorical variables,
were estimated. The betaine groups, highest and lowest quintiles of
betaine excretion (patients taking fibrate excluded), were com-
pared with the middle 60%, and the highest and lowest quintiles of
gender-corrected plasma betaine were compared with the middle
group. Similar models were calculated with plasma homocysteine
and plasma N,N-dimethylglycine groups. Most of the potential
prognostic markers identified in Table 2 were either significant
contributors to these models (Table 4) or showed a trend (p,0.1)
that would justify further investigation.
Discussion
Betaine metabolism and coronary artery disease
Our results are direct evidence that both high and low plasma
betaine concentrations are associated with an increased coronary
risk, a common pattern with essential homeostatically controlled
metabolites. These observational results do not establish causality,
and were obtained on a selected population with a pre-existing
high risk of further events. Betaine (both plasma concentrations
and excretion) is clearly a marker of this risk; betaine excretion is
associated with an increased risk of heart failure rather than MI.
High excretion may persist for years [29] and may cause a betaine
insufficiency, while a primary betaine insufficiency is a likely
reason for an abnormally low excretion. These results support
inferences from cross-sectional data [6], which suggested that there
could be an association between betaine excretion and vascular
disease. Increasing betaine metabolism is a major response to an
increased supply of homocysteine (Figure 1), and this results in an
elevation in plasma N,N-dimethylglycine, which is also associated
with more events. Low plasma betaine has previously been
associated with an unfavorable risk profile in a general adult
population [7], particularly in the metabolic syndrome, and a
similar significant association of low plasma betaine with an
unfavorable lipid profile and high BMI was also found in the
present cohort [8]. Another cross-sectional study associated high
plasma betaine with an increased risk of vascular disease [15], and
the present study suggests that these reports are consistent. Our
results could also help to clarify the ‘‘homocysteine controversy’’
[30]. Homocysteine has been reaffirmed as a strong risk factor for,
or marker of, cardiovascular disease [31,32] but using folate
supplementation to lower plasma homocysteine concentrations
does not lead to a decrease in the incidence of secondary events
[17–19]. In the present cohort, homocysteine is confirmed as a
powerful risk factor. This study does not have the power to show
whether modest elevations of plasma homocysteine show a graded
risk increase, but the relationship between plasma homocysteine
and risk is clearly non-linear, and the difference between the
reported mean plasma homocysteine concentrations of the folate-
treated and control groups in the larger studies would not be
associated with a significant difference in risk in our cohort. The
high homocysteine concentrations that we have found to be
associated with an increased risk were also associated with
disturbed betaine metabolism, and the possibility that the larger
study populations included subjects with a betaine insufficiency
appears to have been overlooked.
We found that homocysteine and plasma betaine are indepen-
dent predictors of plasma NT-proBNP; the anomaly that plasma
betaine is also positively associated with NT-proBNP is consistent
with the negative association between the natriuretic peptide and
obesity [33,34], since plasma betaine is also negatively associated
with obesity [7]. The association of NT-proBNP with betaine is
stronger than with BMI or blood lipids and is confounded by a
trend for NT-proBNP to also increase when plasma betaine is low
(Figure 4), an observation that supports the conclusion that both
low and elevated plasma betaine are associated with pathological
changes. A recent cross-sectional study has suggested that the
association between NT-proBNP and homocysteine is linked
through impaired fatty acid oxidation [35]. While it is clear that
plasma betaine, betaine metabolism and betaine excretion are
markers of outcome, it has not been established that they are
independent of other markers, or that betaine has a mechanistic
role in the pathology. There were too few events in this study to
establish the increase in risk associated with markers of betaine
metabolism (as shown by the wide confidence intervals in Table 4),
but the preliminary evidence suggests that these possibilities should
be investigated.
Table 4. Cox regression models.
Prognostic marker (for
outcome) Outcome Hazard ratio (CI) p-value
Top quintile plasma betaine HF 1.4 (0.7–3.0) 0.30
Top quintile plasma betaine MI 1.2 (0.6–2.2) 0.64
Top quintile plasma betaine Death 0.5 (0.2–1.5) 0.22
Bottom quintile plasma betaine HF 1.2 (0.5–2.9) 0.63
Bottom quintile plasma betaine MI 1.9 (1.1–3.5) 0.034
Bottom quintile plasma betaine Death 0.9 (0.4–2.3) 0.90
Top quintile urine betaine
excretion
HF 2.7 (1.05–2.7) 0.039
Top quintile urine betaine
excretion
MI 1.0 (0.5–2.2) 0.99
Top quintile urine betaine
excretion
Death 0.6 (0.2–1.8) 0.37
Bottom quintile betaine excretion HF 2.7 (1.05–6.9) 0.046
Bottom quintile betaine excretion MI 1.0 (0.4–2.3) 0.93
Bottom quintile betaine excretion Death 0.2 (0.02–1.2) 0.077
Top quintile plasma DMG HF 1.6 (0.8–3.1) 0.20
Top quintile plasma DMG MI 1.7 (0.9–3.2) 0.076
Top quintile plasma DMG Death 1.7 (0.5–3.4) 0.10
Top quintile plasma homocysteine HF 3.0 (1.4–6.2) ,0.001
Top quintile plasma homocysteine MI 2.6 (1.4–4.7) 0.002
Top quintile plasma homocysteine Death 2.1 (0.9–4.8) 0.082
Cox proportional hazards regression models with admission for heart failure
(HF, acute myocardial infarction (MI) or death (all causes) as the outcomes.
Models included left ventricular ejection fraction (LVEF) and age as continuous
variables. Categorical variables were gender, and high, middle or low plasma
betaine concentration or urine betaine excretion (Table 2), or plasma
homocysteine or N,N-dimethylglycine (DMG): the middle 60% group used as
the reference group. Significant (p,0.05) markers in bold. DMG: N,N-
dimethylglycine. CI: 95% confidence interval.
doi:10.1371/journal.pone.0037883.t004
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Betaine is essential for cell volume regulation [1–4] and most
tissues contain millimolar concentrations of intracellular betaine
[9], much higher than circulating concentrations. This tissue
betaine (Figure 1) is also a major store of methyl groups for the
methylation processes that are essential for diverse functions,
including creatine phosphate and phospholipid biosynthesis and
the epigenetic control of gene expression. Therefore a betaine
insufficiency may itself be pathogenic. Betaine insufficiency may
be common in the metabolic syndrome [3,7], and betaine deficient
subjects may be at greater risk of cardiovascular events. This
hypothesis is difficult to test because plasma betaine is regulated
and does not appear to change with tissue betaine, for example, in
diuresis and antidiuresis [12]. Plasma betaine is a poor measure of
tissue betaine [9]. Some subjects, especially those with diabetes
mellitus [3] lose excessive amounts of betaine and these indeed do
have a significantly increased risk of heart failure. In subjects with
diabetes high betaine excretion is associated with the loss of
another renal osmolyte, sorbitol [36]. Betaine loss may persist for
years [29], and the amount lost is often comparable with the
normal daily betaine intake. Such subjects are candidates for a
secondary betaine insufficiency. Normal betaine excretion prob-
ably reflects loss from the renal medulla during osmoregulation
[37] rather than incomplete tubular resorption because it does not
correlate with plasma betaine [3], is low (the fractional clearance is
less than 2%) but approximately constant for individual subjects
[12,14], and is minimally affected by either osmotic status [13] or
by betaine intake [10,11]. Unusually low betaine excretions may
reflect a primary betaine deficiency, which could be a result of
poor diet or impaired mitochondrial oxidation of choline. This is
speculative, but it would explain why low betaine excretion also
appears to be associated with secondary cardiovascular events and
with elevated plasma homocysteine in the present population.
The possibility that high plasma betaine concentrations may
also be a risk factor [15] probably reflects a different pathology, for
example, a dysfunction in the control of betaine efflux from tissues,
where betaine concentrations are much higher than in blood [9].
Efflux is normally tightly regulated [38,39], so a high blood
concentration could be associated with a tissue insufficiency.
Alternatively, high plasma betaine could result from decreased
betaine homocysteine methyltransferase activity, as has been
observed in animal models [40,41]. In our study a minority of
subjects who had events had high plasma betaine concentrations,
and these subjects tended to have early events; this was especially
evident in patients with diabetes, consistent with significant tissue
damage at baseline. The contrast between patients with and
without diabetes points to differences in the sample populations as
an explanation for the contradictions between cross-sectional
studies where low plasma betaine is associated with unfavourable
vascular risk profiles [7,8] and those where high plasma betaine
appears as a risk factor [15].
Betaine insufficiency and homocysteine
The most satisfactory test for betaine status, the methionine load
test [2,3,16], is not appropriate for screening seriously ill subjects.
Fasting homocysteine is also affected by the availability of betaine
[3,16], a result of the action of the liver and renal enzyme betaine-
homocysteine methyltransferase which catalyzes the remethylation
of homocysteine to methionine, the other product being N,N-
dimethylglycine (Figure 1). The importance of this pathway has
been demonstrated by blocking [40] or deleting [41] this enzyme,
leading to a large increase in plasma homocysteine with a
simultaneous increase in plasma betaine. Since this is the only
known metabolic source of dimethylglycine, an increase in plasma
dimethylglycine indicates that betaine is being consumed, though
its rapid clearance means that this may not be a sensitive test with
fasting samples. Fasting plasma homocysteine is well-known to be
affected by vitamin intake (particularly folate and B12) as well as by
the betaine supply, making this a nonspecific test.
The results reported here confirm that elevated homocysteine is
a strong risk factor for later events in people with established
coronary artery disease, though the overall result is mainly
attributable to a small number of subjects with exceptionally
elevated (.20 mmol/L) plasma homocysteine concentrations. A
number of intervention studies in recent years have shown that
lowering plasma homocysteine in large populations by supplying
folate and other B-vitamins does not decrease the incidence of
secondary vascular events [17–19]. This anomaly could be
resolved if some of the cases of elevated homocysteine in subjects
with vascular disease reflect betaine insufficiency, which is
plausible because the metabolic syndrome is likely to be common
in these subjects. Folate supplementation will not correct a betaine
insufficiency. It lowers homocysteine in most subjects, but the
reduction in risk is relatively small in subjects with normal or only
mildly elevated homocysteine concentrations, compared with the
large risk associated with plasma homocysteine .20 mmol/L. A
majority of the examples of highly elevated plasma homocysteine
appear to be associated with evidence of a betaine insufficiency,
and the subjects with both high homocysteine and possible betaine
insufficiency are at greater risk of secondary events, especially
heart failure.
Betaine sufficiency and blood lipids
Given that betaine is highly water soluble and lipophobic, it is
surprising that the supply of betaine affects lipid metabolism, with
the varied explanations unconvincing [3,5]. Human cross-section-
al studies have suggested that that these relationships are relevant
in human populations [7] including the present one [8], and that
low plasma betaine concentration is associated with the metabolic
syndrome and known prognostic markers of vascular disease. In
subjects with elevated blood lipids, betaine loss in the urine is
associated with elevated plasma homocysteine [42,43]. These
relationships have been discussed elsewhere for the present
population [8,43]. Lipid lowering drugs do have an effect: fibrates
appear to strongly affect the urinary excretion of betaine [28] and
therefore subjects taking fibrates were excluded when the urinary
results were analyzed here. Statin therapy is associated with a mild
increase in plasma betaine concentrations [8,43] but the difference
is small compared with the gender difference. Other cardiovas-
cular drugs also may affect betaine handling [43]. Given that most
of the evidence is cross-sectional, it is not at all clear whether
betaine deficiency causes dyslipidemia, is a consequence of
dyslipidemia, or both are markers of an underlying pathology,
and this needs to be clarified.
Should betaine insufficiency be corrected?
Our results are consistent with the hypothesis that a tissue
betaine insufficiency will increase the incidence of secondary heart
failure. Impaired osmoregulation may be an important mecha-
nism. Betaine insufficiency may also increase the incidence of
secondary MI, but the evidence is less persuasive, since low plasma
betaine concentrations and increased metabolism to dimethylgly-
cine could be the result rather than the cause of disease. Possibly
the role of betaine as a methyl store may be more significant for
risk of MI. These inferences are speculative on the basis of our
observational evidence, but they suggest that interventional studies
are justified.
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37883Betaine supplementation is inexpensive and safe [1,3,44]. It has
been used in the animal industries to decrease the fat content, and
increase the lean muscle mass, of meat [5]; it improves the
atherogenic risk factor profile of a mouse model [45], and in an
apolipoprotein E-deficient mouse model attenuates atherosclerotic
lesions [46]. It has recently been used to enhance human athletic
performance measures such as power and endurance [47–49].
Therefore, in the absence of a simple test for betaine sufficiency,
the hypotheses suggested here could be best be addressed directly,
initially by some pilot randomized controlled trials of betaine
supplementation using appropriately selected at-risk populations.
Limitations
The main limitations of this study are inherent in the chosen
population: this clinical cohort is not representative of the general
population. Because the subjects have existing disease, there is
ambiguity about the extent to which the markers are detecting
base line disease or are prognostic of the development of new
disease. The small number of subjects with diabetes limits the
power to detect effects in this sub-group and negative results on
these patients are inconclusive. The observational results do not
provide insights into mechanisms and can only generate hypoth-
eses.
Conclusions
Disturbances in betaine homeostasis are associated with
secondary events in an acute coronary syndrome cohort. Betaine
insufficiency should be considered as a possible cause of elevated
homocysteine. The possibility that correcting betaine insufficiency
could improve outcomes should be investigated.
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